Transforming the Treatment of Heart Failure
The Corvia Atrial Shunt is a novel heart failure (HF) therapy specifically designed to reduce the symptoms associated with high pressures in the heart and lungs. It is the world’s first atrial shunt intended to reduce heart failure hospitalizations and improve quality of life.
Now enrolling!
RESPONDER-HF
Clinical Study
Consider giving your HF patients with EF≥40% a new opportunity to find relief.
Has Heart Failure
Left You Breathless?
Relief may be possible with the Corvia® Atrial Shunt. See if you’re eligible for the RESPONDER-HF study.
REDUCE LAP-HF II
3-Year Results now Available
Review the results of Corvia Atrial Shunt therapy from the world’s most extensive study of atrial shunting.
Which patients are appropriate for Corvia Atrial Shunt Therapy?
Dr. Jim Udelson, Dr. Sanjiv Shah, and Dr. C. Michael Gibson discuss the importance of appropriate patient selection.
Recent 2-year echocardiographic data from REDUCE LAP-HF II
Evidence of the favorable long-term effect of the Corvia Atrial Shunt on heart structure and function.
675+ Patients
have received the Corvia Atrial Shunt
18 Countries
in which the Corvia Atrial Shunt has been implanted
100+ Hospitals
with Corvia Atrial Shunt experience
10+ Years
post-implant for the first Corvia Atrial Shunt patients
Seeing is believing
Watch how the Corvia Atrial Shunt is implanted and how it works to reduce heart failure symptoms.
RESPONDER-HF Clinical Study
A clinical trial to confirm the efficacy of the Corvia Atrial Shunt in heart failure patients with EF≥40%
Find a Participating Clinical Trial Center
Find a center that offers the Corvia Atrial Shunt System.